# BH-30643

Source: https://onco.cc/drugs/bh-30643/  
OnCo record `bh-30643` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BH-30643 is an experimental small molecule from BlossomHill Therapeutics, in phase 1 trials for EGFR-mutant non-small cell lung cancer and HER2-mutant non-small cell lung cancer.

## Summary

BH-30643 (OMNI-EGFR inhibitor) is a small molecule (oral, non-covalent, macrocyclic) from BlossomHill Therapeutics. An orally bioavailable, non-covalent, macrocyclic, brain-active, mutant-selective EGFR inhibitor designed to overcome the limitations of currently approved EGFR inhibitors, with selectivity over wild-type EGFR. Its furthest stage is phase 1, for EGFR-mutant non-small cell lung cancer and HER2-mutant non-small cell lung cancer. ClinicalTrials.gov registers it in one study linked below. Company pipeline shows Phase 1; the SOLARA registry entry is phase 1/2, recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: OMNI-EGFR inhibitor
- Tags: pipeline; ctgov-ingest
- Code: BH-30643
- Modality: Small molecule (oral, non-covalent, macrocyclic)
- Mechanism: An orally bioavailable, non-covalent, macrocyclic, brain-active, mutant-selective EGFR inhibitor designed to overcome the limitations of currently approved EGFR inhibitors, with selectivity over wild-type EGFR.

## Sources

- BlossomHill Therapeutics: bhtherapeutics.com: https://www.bhtherapeutics.com/pipeline
- BlossomHill Therapeutics: bhtherapeutics.com: https://www.bhtherapeutics.com/pipeline
- BlossomHill Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT06706076
- ClinicalTrials.gov: trials of BH-30643: https://clinicaltrials.gov/search?intr=BH-30643

## Connected records

- cancers: [HER2-mutant non-small-cell lung cancer](https://onco.cc/cancers/her2-mutant-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- companies: [BlossomHill Therapeutics](https://onco.cc/companies/blossomhill-therapeutics/)
- trials: [A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations](https://onco.cc/trials/nct06706076/)

---
JSON: https://onco.cc/api/v1/entities/bh-30643.json